Get the content you want anytime you want.
REGISTER NOW | SIGN IN
VIDEO

twoXAR: Developing Novel Lupus Therapies Amid COVID 19 Research Complications

JUN 18, 2020 | CONTAGION® EDITORIAL STAFF

Segment Description: Vibeke Strand, MD, MACR, FACP, Adjunct Clinical Professor in the Division of Immunology/Rheumatology professor at Stanford University School of Medicine, discusses AI research in her field and patients who are having a hard time getting their usual supplies of HCQ during the COVID-19 pandemic.

Related Coverage:  FDA Revokes Emergency Authorization for Chloroquine, Hydroxychloroquine

The US Food and Drug Administration (FDA) has revoked the Emergency Use Authorization (EUAs) for hydroxychloroquine and chloroquine in treating coronavirus 2019 (COVID-19). 

The decision comes with context in a letter written by Denis M. Hinton, chief scientist of the FDA, to the Biomedical Advanced Research and Development Authority (BARDA) on Monday morning. BARDA Deputy Assistant Secretary and Director of the Medical Countermeasure Programs Gary L. Disbrow, PhD, originally wrote the FDA requesting the 2 malaria drugs be revoked of their EUAs on the basis of continuously evolving public health response information.

Read the full story.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.